China National Medicines Corporation Ltd. (SHA:600511)
China · Delayed Price · Currency is CNY 28.30
+0.18 (0.64%)
Jul 31, 2026, 3:00 PM CST
SHA:600511 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21,352 | 21,692 | 25,819 | 21,594 | 21,051 | 23,789 | |
Market Cap Growth | -5.57% | -15.98% | 19.57% | 2.58% | -11.51% | -36.06% |
Enterprise Value | 15,829 | 16,505 | 20,034 | 15,889 | 16,871 | 19,902 |
Last Close Price | 28.30 | 27.93 | 32.34 | 26.36 | 25.17 | 27.74 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 10.61 | 10.86 | 12.91 | 10.06 | 10.72 | 13.56 |
Forward PE | 10.18 | 10.25 | 10.71 | 8.91 | 10.01 | 12.87 |
PS Ratio | 0.40 | 0.41 | 0.51 | 0.44 | 0.46 | 0.51 |
PB Ratio | 1.03 | 1.07 | 1.36 | 1.23 | 1.33 | 1.66 |
P/TBV Ratio | 1.15 | 1.20 | 1.55 | 1.41 | 1.53 | 1.93 |
P/FCF Ratio | 89.54 | 11.20 | 16.89 | 8.37 | 9.29 | 12.77 |
P/OCF Ratio | 69.84 | 10.82 | 15.56 | 7.92 | 8.79 | 12.15 |
PEG Ratio | - | 5.13 | 1.53 | 0.69 | 1.03 | 1.03 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.30 | 0.32 | 0.40 | 0.32 | 0.37 | 0.43 |
EV/EBITDA Ratio | 7.03 | 7.70 | 9.01 | 6.39 | 6.96 | 9.24 |
EV/EBIT Ratio | 7.83 | 8.15 | 9.52 | 6.70 | 7.28 | 9.69 |
EV/FCF Ratio | 66.37 | 8.52 | 13.11 | 6.16 | 7.45 | 10.69 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.05 | 0.03 | 0.03 | 0.05 |
Debt / EBITDA Ratio | 0.23 | 0.23 | 0.36 | 0.21 | 0.21 | 0.31 |
Debt / FCF Ratio | 2.12 | 0.27 | 0.55 | 0.21 | 0.23 | 0.38 |
Net Debt / Equity Ratio | -0.35 | -0.54 | -0.53 | -0.59 | -0.53 | -0.46 |
Net Debt / EBITDA Ratio | -3.41 | -5.11 | -4.52 | -4.18 | -3.46 | -3.07 |
Net Debt / FCF Ratio | -30.63 | -5.66 | -6.57 | -4.02 | -3.70 | -3.55 |
Asset Turnover | 1.50 | 1.47 | 1.50 | 1.60 | 1.58 | 1.76 |
Inventory Turnover | 9.75 | 9.66 | 10.54 | 11.90 | 11.53 | 13.05 |
Quick Ratio | 1.81 | 1.72 | 1.68 | 1.73 | 1.71 | 1.63 |
Current Ratio | 2.18 | 2.08 | 2.04 | 2.04 | 2.02 | 1.93 |
Return on Equity (ROE) | 10.41% | 10.64% | 11.67% | 13.98% | 14.09% | 14.05% |
Return on Assets (ROA) | 3.55% | 3.54% | 3.90% | 4.78% | 5.03% | 4.85% |
Return on Invested Capital (ROIC) | 14.24% | 17.81% | 21.00% | 25.82% | 24.13% | 21.03% |
Return on Capital Employed (ROCE) | 9.30% | 9.50% | 10.50% | 12.80% | 13.70% | 13.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.42% | 9.20% | 7.75% | 9.94% | 9.33% | 7.37% |
FCF Yield | 1.12% | 8.93% | 5.92% | 11.96% | 10.76% | 7.83% |
Dividend Yield | 2.83% | 2.86% | 2.47% | 3.24% | 3.11% | 2.52% |
Payout Ratio | 30.91% | 31.34% | 34.12% | 33.06% | 31.16% | 36.36% |
Buyback Yield / Dilution | -0.00% | -0.00% | -0.00% | 0.00% | 0.00% | -0.00% |
Total Shareholder Return | 2.82% | 2.86% | 2.47% | 3.24% | 3.11% | 2.52% |